Login to Your Account

Kite 'ZUMAs' to BLA as phase II CAR-T study meets primary endpoint

By Marie Powers
News Editor

Monday, September 26, 2016

After Monday's market close, Kite Pharma Inc. reported top-line results from a pre-planned interim analysis of the phase II portion of its ZUMA-1 trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription